more news out today..... I'm in @.0049
News for 'HTDS' - (Hard To Treat Diseases (HTDS) To Name New CEO and Directors)
SHENZHEN, China, Jan 21, 2009 /PRNewswire-FirstCall via COMTEX/ -- Hard to
Treat Diseases (HTDS)
www.htdsmedical.com is set to appoint Mr. Terry Yuan as
its new CEO. Terry is the current President and CEO of Shenzhen Mellow Hope
Pharm Industrial Co., Ltd. (Mellow Hope),
www.mellowhope.com, a company targeted
for a merger with HTDS. (See previous news Jan 14 2009). The company will
complete the filings on Pink Sheets shortly.
Mr. Terry Yuan will also maintain the same President and CEO position with
Mellow Hope. Shenzhen Mellow Hope Pharm Industrial Co., Ltd. is the biggest
exporter of Biological Vaccines in China. In cooperation with Institutes of
Medical Biology and Pharmaceutical manufacturers, Mellow Hope provides a wide
range of vaccines with high quality, safety and efficacy.
Mr. Terry Yuan said, "We continue our merger discussions with Hard To Treat
Diseases. At present all systems appear to be a go. I know that Andrea Zecevic,
HTDS Chief Project Scientist and Director, R&D has been going over all the
documents we provided and is receiving feedbacks from the doctors team in Serbia
and completing organizing and indexing all submissions. She has done an
extraordinary job in putting the whole team together."
Mr. Keith Roberts outgoing and interim CEO of Hard To Treat Diseases said "We
wish to welcome Mr Terry Yuan aboard HTDS. Save for some highly unlikely and
unforeseen obstruction which may arise, at this point I can safely say nothing
appears to be in the way of this merger. I concur with Terry that on our end it
also appears all systems are a go for this merger. The target date is shaping
out to be the first part of February. Assuming all goes well the "signing
ceremony" will follow in China. My understanding is that the event will be
covered by the Chinese media TV, and news print and medical industry journals in
China."
Mr. Keith Roberts will retain the position of the CFO with the company after the
resignation as a CEO.
The will provide additional updates on developments as they unfold.
Safe Harbor statement under the Private Securities Litigation Reform Act of
1995: Certain information contained in this release contains forward-looking
statements that involve risk and uncertainties, including but not limited to,
those relating to development and expansion activities, domestic and global
conditions, and market competition.
CONTACT: For scientific dialogue and inquiry only Andrea can be reached via
e-mail at
azconsulting2001@gmail.com; For any corporate matters the readers
should contact the company directly at
corporate@htdsmedical.com
SOURCE Hard to Treat Diseases
www.prnewswire.com
Copyright (C) 2009 PR Newswire. All rights reserved